Krebs Biochemicals and Industries Limited (NSE: KREBSBIO) submitted its financial results for the quarter ended June 30, 2026, to the National Stock Exchange on August 6, 2026, following a board meeting held on the same date. The filing marks the company's latest earnings disclosure under SEBI's listing obligations and disclosure requirements framework.
Dividend History: A Two-Decade Gap
The company has not declared any dividend alongside its Q1 FY27 results. A review of KREBSBIO's dividend history on the NSE reveals that the last recorded dividend payout was in June 2005, when the board recommended a cash dividend of ₹3.00 per share for the financial year 2004-05, representing 30% of the face value. No dividend has been announced in the over 21 years since that declaration.
- Last dividend declared: ₹3.00 per share (FY2004-05)
- Dividend declared since FY2005: None on record
- Dividend yield at current market price: Not applicable; no active dividend
For income-focused investors, this extended absence of dividend distribution is a material consideration. The lack of any shareholder payout over two decades suggests the company has consistently prioritised internal capital retention, though the specific deployment of retained earnings would require a detailed examination of annual financials.
Market Data Limitations
At the time of this filing, real-time quote data and trade information for KREBSBIO were not available through the NSE data feed. As a result, precise metrics including the current market price, 52-week high and low range, delivery percentage, price-to-earnings ratio, and sector PE comparison cannot be reported with accuracy in this article. Investors are advised to refer directly to the NSE portal or their trading terminals for live price and volume data before making any assessment of valuation metrics.
Company Background
Krebs Biochemicals and Industries Limited is an ISIN INE268B01013-registered entity listed on the NSE. The company operates in the biochemicals and industrial chemicals segment. It has maintained its listing continuously since at least the early 2000s, with the NSE serving as its primary exchange for disclosure and trading purposes.
What the Results Filing Means for Investors
The submission of quarterly financial results for the period ended June 30, 2026, is a mandatory compliance event under SEBI's Listing Obligations and Disclosure Requirements Regulations. Investors should note the following key points from this announcement cycle:
- The board meeting held on August 6, 2026, was convened to approve and adopt Q1 FY27 financials.
- No dividend, bonus, or other corporate action was announced alongside the results.
- The dividend track record shows a single payout in over two decades of exchange history, indicating a non-dividend-paying profile for the stock.
- Investors seeking income through dividends should factor in this historical pattern when evaluating KREBSBIO against sector peers.
The actual revenue, EBITDA, net profit, and year-on-year performance figures from the Q1 FY27 results will be available in the detailed financial statement attached to the NSE announcement. Investors are encouraged to review the complete filing on the NSE EDGAR portal under the KREBSBIO symbol for a full assessment of operational and financial performance for the quarter.